2026 is set to be a year of transition for the Danish drugmaker, as it faces headwinds including lower pricing on multiple fronts and patent expiries in Brazil, Canada, and China. It follows a ...

American patients can now receive the first-ever GLP-1 pill for weight loss from Novo Nordisk, marking a new chapter of obesity treatment in the U.S. The cash prices for the drug, called the Wegovy ...

Novo Nordisk has won the race to secure approval from the U.S. Food and Drug Administration for the first weight-loss drug to be administered orally. Jules Rimmer is a markets reporter in ...

Novo launches Wegovy pill in competitive obesity drug market Eli Lilly expects weight-loss pill decision later this year Novo targets self-pay market with oral option over injectable Starter dose of ...

The Wegovy pill is the first and only oral GLP-1 for weight loss in adults. The first and only oral GLP-1 for weight loss in adults is now available to consumers. Drugmaker Novo Nordisk announced ...

Novo Nordisk received FDA approval for oral Wegovy, but unit economics are structurally unfavorable due to poor bioavailability and high API requirements. I cut my rating to Sell (market underperform) ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Novo Nordisk plans to ...

Dec 29 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab and Eli Lilly (LLY.N), opens new tab are lowering prices of their top-selling obesity drugs Wegovy and Mounjaro in China, according to the ...

Novo Nordisk launched the first GLP-1 weight-loss pill Monday with a pledge that manufacturing investments will enable the drugmaker to avoid the type of shortages that plagued the rollout of its ...

Novo Nordisk (NVO) announced on Wednesday that the Supreme People’s Court in China issued a favorable ruling related to the compound patent of semaglutide, the main ingredient in its blockbuster ...

No pharmaceutical stock investor likes it when one of their holdings slices drug prices. This one is reducing the costs of a top medicine in a huge Asian market. The cost of Wegovy is about to ...

Novo Nordisk’s wildly successful obesity medicine is now available as a pill, making it the first GLP-1 pill for weight loss in the United States. The pill is available in four doses and is cheaper ...